WEDNESDAY, JULY 22 · DAILY EDITION
Daily Market Brief — July 22, 2026
Today's market is driven by strong financial results from NCAB Group and a positive guidance update from GEA Group, while other announcements have a neutral or negative impact. The top filings since yesterday show a mix of positive and neutral news, with some companies reporting strong growth and others facing financial challenges.
0AAQRNSpositive
NCAB Group Reports Strong Q2 Results
NCAB Group reported a 25% increase in net sales and a 59% surge in order intake, resulting in a book-to-bill ratio of 1.34, with EBITA rising to SEK 138.6 million and profit after tax at SEK 84.4 million.
VIEW FILING →
0MPJRNSpositive
GEA Group Raises Full-Year Guidance
GEA Group Aktiengesellschaft has raised its full-year guidance for 2026 after a strong second quarter, with preliminary results showing a 14.2% increase in order intake and a 10.0% rise in revenue.
VIEW FILING →
0MPJRNSpositive
GEA Group's Q2 Results Exceed Expectations
GEA Group Aktiengesellschaft's preliminary Q2 2026 results exceeded market expectations, with order intake and revenue showing significant organic growth, leading to an increase in full-year 2026 guidance.
VIEW FILING →
10-K/Anegative
Starfighters Space Auditor Raises Concerns
The company's auditor has expressed substantial doubt about its ability to continue as a going concern due to net losses, negative cash flows, and an accumulated deficit, which raises concerns about its financial stability.
VIEW FILING →
NAVFRNSnegative
Nippon Active Value Fund Issues New Shares
The company issued 980,000 new shares at 227.00 pence, a premium to the prevailing net asset value, which may lead to short-term dilution for existing shareholders.
VIEW FILING →
0ABGRNSneutral
Swedencare AB Reports Q2 Results
Swedencare AB reported a 4% increase in net revenue and a 5% rise in operational EBITDA for the second quarter, with improved profit after tax and operating cash flow.
VIEW FILING →
0MH6RNSneutral
Ipsen Completes Acquisition of Memo Therapeutics
Ipsen's acquisition of Memo Therapeutics AG adds a first-in-class asset to its Rare Disease pipeline, strengthening its position in the market.
VIEW FILING →
0R3MRNSneutral
Vivoryon Therapeutics NV to Report H1 2026 Results
The announcement of H1 2026 financial results and business updates is routine and already priced in, with no quantified surprise.
VIEW FILING →
AMRQRNSneutral
Amaroq Ltd Announces Board Changes
The announcement of board changes, including a new Chairman and the appointment of new independent non-executive directors, is a routine corporate update that does not contain any quantified surprises or significant new information.
VIEW FILING →
NDAQEUneutral
Listing of Mini Futures on Nasdaq Stockholm
This notice is about the listing of mini futures issued by J.P. Morgan SE on Nasdaq Stockholm, which is a routine market operation and does not contain any quantified surprises or significant events.
VIEW FILING →
Get tomorrow's brief
The filings and moves that matter, in your inbox every market day.
Subscribe free →